<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:chebi fb="4" ids="30413">Heme</z:chebi> oxygenase-1 (HO-1) is an inducible Phase 2 enzyme that degrades toxic <z:chebi fb="4" ids="30413">heme</z:chebi>; its role in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> is not fully understood </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesize that chemically induced HO-1 upregulation with the novel <z:chebi fb="0" ids="36615">triterpenoid</z:chebi> CDDO-Im (2-cyano-3,12 dioxooleana-1,9 dien-28-oyl <z:chebi fb="1" ids="53094">imidazoline</z:chebi>), a robust inducer of Phase 2 genes, protects neurons against ischemic injury </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Using 3 different models of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, including oxygen-<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation in neuronal cultures, global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in rats, and focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in mice, we determined (1) whether CDDO-Im induces HO-1 expression and protects against ischemic injury; and (2) whether HO-1 inhibition disrupts the neuroprotective effect of CDDO-Im </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: CDDO-Im treatment (50-300 nmol/L) resulted in 8-fold HO-1 upregulation in cultured neurons and protected against oxygen-<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation </plain></SENT>
<SENT sid="4" pm="."><plain>The protection was abolished when the cultures were transfected with nuclear factor (erythroid-derived 2) like-2-shRNA or coincubated with tin <z:chebi fb="0" ids="15430">protoporphyrin</z:chebi> IX, a specific HO-1 inhibitor </plain></SENT>
<SENT sid="5" pm="."><plain>In the rat model of global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, intracerebroventricular infusion of CDDO-Im (0.5-1.5 μg) augmented HO-1 expression in hippocampal neurons and resulted in significant increases in CA1 neuronal survival after global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>To further strengthen the clinical relevance of the CDDO-Im treatment, we tested its effects in the mouse model of temporary focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (60 minutes) </plain></SENT>
<SENT sid="7" pm="."><plain>Postischemic intraperitoneal injection of CDDO-Im (10-100 μg) enhanced HO-1 expression and significantly reduced neurological dysfunction and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="8" pm="."><plain>Intracerebroventricular infusion of tin <z:chebi fb="0" ids="15430">protoporphyrin</z:chebi> IX reduced the neuroprotective effect of CDDO-Im against global and focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: CDDO-Im confers neuroprotection against ischemic injury by upregulating HO-1, suggesting that enhance of HO-1 expression may be a legitimate strategy for therapeutic intervention of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>